Loading
RenovoRx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bagai Shaun, was filed 24 Mar 2026.
RenovoRx, Inc.: what insiders have been doing
RenovoRx, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (21 October 2025 to 21 October 2026), 14 filings came from 4 insiders.
Not one open-market sale was filed. On the buying side, 4 insiders reported 11 purchases totalling €47k. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 2 senior executives, 1 finance chief and 1 chief executive among the declarants. Agah Ramtin filed the largest purchase, €8,677, on 17 December 2025.
In all, 4 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 24 March 2026, 211 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 14 filings here. Our records for RenovoRx, Inc. go back to 2022, with 30 purchases and no sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 1.1 m USD of revenue and -11.2 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
38
Thresholds
n/a
Buy Volume
€190,707
30 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleRamtin Agah11 buys
Shaun Bagai8 buys
Laurence Marton2 buys
Mark Voll1 buy
Ron Kocak1 buy
Since the insiders bought
- -17.2%Entry US$1.10 · Close at T+90 US$0.91
- -9.6%Entry US$1.00 · Close at T+90 US$0.90
- +32.1%Entry US$0.77 · Close at T+365 US$1.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,044 of 26,279 companies
27.6
score / 100
Value10
Quality45
FCF yld-20%
Earn yld-21%
EV/EBITDA·
ROE-125%
Gross mgn71%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.15
Analyst consensus
4 analysts1.00/5
US$3.00Target US$7.13(+520%)US$14.50
Income statement
RevenueUS$1.1M
Gross profitUS$796k71% margin
EBITDA-US$12.5M-1114% margin
Net income-US$11.2M-994.5% margin
Valuation
PER (forward)-9.6x
P/Book5.8x
Beta0.97
Balance sheet & cash
Market capUS$51.9M
Total debtUS$212k
Free Cash Flow-US$11M
Debt / Equity4%
Profitability & ownership
ROE-125.2%
ROA-64.9%
% insiders3.6%
% institutions20.4%
Last declaration on 15 September 2026
Declarations38 total
24,300 sharesCommon StockSEC:0001493152-26-012482:0
Canonical exit: 18 Jun 2026 (T+90)
9,720 sharesCommon StockSEC:0001493152-26-012483:0
Canonical exit: 18 Jun 2026 (T+90)
10,000 shares@ US$0.99756.4% of flowCommon StockSEC:0001493152-26-003181:0
Canonical exit: 21 Apr 2026 (T+90)
9,795 shares@ US$0.865.4% of flowCommon StockSEC:0001493152-26-000255:0
Canonical exit: 31 Mar 2026 (T+90)
205 shares@ US$0.8260.1% of flowCommon StockSEC:0001493152-26-000157:0
Canonical exit: 30 Mar 2026 (T+90)
5,000 shares@ US$0.90138.1% of flowCommon StockSEC:0001493152-25-028650:0
Canonical exit: 18 Mar 2026 (T+90)
5,000 shares@ US$0.85247.7% of flowCommon StockSEC:0001493152-25-028439:0
Canonical exit: 17 Mar 2026 (T+90)
12,000 shares@ US$0.856.5% of flowCommon StockSEC:0001493152-25-028057:0
Canonical exit: 16 Mar 2026 (T+90)
10,000 shares@ US$0.966.2% of flowCommon StockSEC:0001493152-25-026516:0
Canonical exit: 5 Mar 2026 (T+90)
10,000 shares@ US$0.805.2% of flowCommon StockSEC:0001493152-25-024875:0
Canonical exit: 19 Feb 2026 (T+90)
5,000 shares@ US$0.94958.6% of flowCommon StockSEC:0001641172-25-025459:0
Canonical exit: 20 Nov 2025 (T+90)
5,000 shares@ US$0.90988.3% of flowCommon StockSEC:0001641172-25-025459:1
Canonical exit: 23 Nov 2025 (T+90)
21,000 shares@ US$1.4019.2% of flowCommon StockSEC:0001641172-25-014212:0
Canonical exit: 3 Sept 2025 (T+90)
400,000 shares0Common StockSEC:0001641172-25-014112:0
20,480 shares@ US$0.154.8% of flowCommon StockSEC:0001641172-25-008842:0
15,000 shares@ US$0.908.9% of flowCommon StockSEC:0001641172-25-005139:0
Canonical exit: 14 Jul 2025 (T+90)
7,500 shares@ US$0.909512.8% of flowCommon StockSEC:0001641172-25-004955:0
Canonical exit: 14 Jul 2025 (T+90)
20,000 shares@ US$0.8010.6% of flowCommon StockSEC:0001641172-25-003951:0
Canonical exit: 10 Jul 2025 (T+90)
10,000 shares@ US$0.8316.0% of flowCommon StockSEC:0001641172-25-003504:0
Canonical exit: 8 Jul 2025 (T+90)
30,000 shares@ US$0.813316.7% of flowCommon StockSEC:0001641172-25-003631:0
Canonical exit: 8 Jul 2025 (T+90)
25 of 38 declarations
About RenovoRx, Inc.
RenovoRx, Inc. is a company focused on developing targeted therapies for cancer treatment. It specializes in local drug delivery to enhance treatment efficacy.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
